Procyrion news & MEDIA

ALL
Press Releases
Articles
Publications
Awards

Fierce Biotech

Procyrion is proud to be recognized as a Fierce15 Medtech company this year! Check out the interview with our CEO Eric Fain to learn more about our innovative Aortix™ technology and the potential it has to change the way patients with acute decompensated heart failure and cardiorenal syndrome are treated.

March 4, 2024
  • Articles
  • Articles

Procyrion Recognized in Fierce Medtech's Fierce15 of 2023

Press Release

Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today the completion of a $57.7 million Series E funding round, including the conversion of $10.0 million of interim financing.

February 5, 2024
  • Press Releases

Procyrion Closes $57.7 Million in Series E Financing

Press Release

Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced the enrollment of the first patients in the company's IDE pivotal trial.

November 30, 2023
  • Press Releases

Procyrion Announces First Patient Enrollments in the DRAIN-HF Pivotal IDE Trial for Aortix™ Percutaneous Mechanical Circulatory Support Technology

Press Release

Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today it has successfully secured new inpatient hospital ICD-10-PCS procedure codes applicable to its Aortix™ percutaneous mechanical circulatory support (pMCS) technology.

September 7, 2023
  • Press Releases

Procyrion Secures New Medicare Payment Codes Applicable to its Aortix™ Percutaneous Mechanical Circulatory Support Technology

Press Release

Procyrion, Inc. announced today that use of its Aortix™ percutaneous mechanical circulatory support (pMCS) device led to rapid decongestion in a pilot study of patients admitted to the hospital with acute decompensated heart failure (ADHF) and worsening renal function, which is known as cardiorenal syndrome (CRS).

March 21, 2023
  • Press Releases

Aortix™ Pump Therapy Leads to Rapid Decongestion and Improved Kidney Function in Hospitalized Patients with Heart Failure and Worsening Renal Function

Press Release

Procyrion announces successful first-in-human cases with Aortix™ pump to prevent acute kidney injury in patients undergoing cardiac surgery. Study adds to the growing body of data for the Aortix™ pump, which will be featured in a presentation at the Technology and Heart Failure Therapeutics conference in March.

February 22, 2023
  • Press Releases

Procyrion Announces Successful First-in-Human Cases with Aortix™ Pump to Prevent Acute Kidney Injury in Patients Undergoing Cardiac Surgery

Press Release

Procyrion’s Aortix™ Percutaneous Mechanical Circulatory Support Device to be Showcased at TCT 2021 Annual Meeting

November 2, 2021
  • Press Releases

Procyrion’s Aortix™ Percutaneous Mechanical Circulatory Support Device to be Showcased at TCT 2021 Annual Meeting

Press Release

Procyrion Announces Successful First-in-Human Cases in Cardiorenal Syndrome (CRS) Patients with Aortix™ Percutaneous Mechanical Circulatory Support Device

May 25, 2021
  • Press Releases

Procyrion Announces Successful First-in-Human Cases in Cardiorenal Syndrome (CRS) Patients with Aortix™ Percutaneous Mechanical Circulatory Support Device

Press Release

Av Edidin, Ph.D., brings > 25 years of in depth experience as a global medical device leader, and will help Procyrion prepare for upcoming clinical studies of the Aortix™ system for the treatment of in-hospital cardiorenal patients.

August 6, 2019
  • Press Releases

Procyrion Names Av Edidin, Ph.D., as Senior Vice President of Development and Manufacturing

Press Release

• Resting the heart while perfusing the kidneys, Aortix aims to treat heart failure symptoms by disrupting the cardiorenal syndrome cycle • Potential to offer significant advantages for patients with acute decompensated heart failure (ADHF) who also have worsening renal function

July 30, 2019
  • Press Releases

Procyrion Receives FDA Breakthrough Device Designation for Aortix™ System

Press Release

The $30M Series D funding, led by a new investor, Bluebird Ventures, will support the Aortix's pilot study through the submission of an FDA IDE application for its pivotal trial.

July 9, 2019
  • Press Releases

Procyrion Raises $30 Million Series D to Support Clinical Trials of its Aortix™ Percutaneous Blood Pump for Treating Heart Failure Patients

Press Release

Procyrion awarded the Most Innovative Heart Pump Technology award in the 2018 Global Healthcare and Pharmaceutical Awards for their device, Aortix™, a catheter-deployed circulatory support device designed initially to address cardiorenal syndrome in heart failure patients.

August 23, 2018
  • Press Releases
  • Awards

Procyrion Named Most Innovative Heart Pump Technology in 2018 Global Healthcare and Pharmaceutical Awards

Press Release

The Board of Directors has chosen Dr. Fain—with > 30 years of experience—to build upon the foundation of innovative technology established over recent years and accelerate the progression of product development leading to human clinical trials and commercialization of the company’s novel and proprietary heart pump.

July 23, 2018
  • Press Releases

Procyrion Selects Former Abbott/St. Jude Medical Group President Dr. Eric S. Fain as CEO

Press Release

The company has added five team members in the past sixty days on the heels of closing $16 Million Series C.

July 10, 2018
  • Press Releases
  • Press Releases

Medical Device Company Procyrion, Inc. Hires Three to Support Growth; Continues to Build Team

Press Release

Procyrion wins best overall medical device product in 2018 MedTech Breakthrough Awards

July 2, 2018
  • Awards

Procyrion, Inc. Wins Best Overall Medical Device Product in 2018 MedTech Breakthrough Awards

Press Release

Procyrion, Inc. received ISO 13485:2016 certification for Medical Device and Quality Management Systems. This certification is a requirement for regulatory purposes and is an international standard that outlines the requirements for a quality management system specific to the medical devices industry.

May 22, 2018
  • Press Releases

Procyrion, Inc. Announces ISO 13485:2016 Certification

Press Release

Procyrion, Inc. announced today the appointment of Tara Burt as Associate Director Clinical Affairs. Burt’s knowledge of clinical strategy, trial execution and operations will be a commanding asset to Procyrion as it continues to advance its intra-aortic heart pump for use in NYHA Class III-IVa heart failure patients

April 30, 2018
  • Press Releases

Procyrion, Inc. Appoints Clinical Operations Pro Tara Burt as Associate Director of Clinical Affairs

Houston Chronicle

When locally based medical device company Procyrion announced a $16 million venture-capital deal in January, it marked a milestone not just for the startup but for Houston as well.

April 12, 2018
  • Articles

Procyrion Featured in The Houston Chronicle: Health-care companies got most venture funds in Houston in Q1

Press Release

Procyrion announces the appointment of Elisabeth (Beth) Neely, RAC, as Senior Vice President of Clinical and Regulatory Affairs. Neely brings to Procyrion more than 20 years of experience as a global regulatory affairs leader, having played a key role in the approval of neuromodulation and cardiac devices.

March 21, 2018
  • Press Releases

Procyrion Names Elisabeth Neely Senior Vice President of Clinical and Regulatory Affairs, Formerly with Abbott

Press Release

Device’s unique cardio-renal effects may provide a novel approach for the treatment of Acutely Decompensated Heart Failure (ADHF)

January 30, 2018
  • Press Releases

Procyrion Raises $16 Million Series C for Clinical Trials of its Breakthrough Aortix™ Heart Pump

Texas Monthly

Procyrion recognized in Texas Monthly Magazine as on of the 15 Innovators Reshaping Texas.

January 29, 2018
  • Articles
  • Publications

Procyrion Honored As An Innovator Reshaping Texas

Scientific American

Procyrion, and its Aortix™ circulatory assist device, was recently recognized in Scientific American as one of "Ten Start-ups Changing Healthcare".

December 18, 2017
  • Articles

Procyrion Recognized as One of "Ten Start-ups Changing Healthcare"

press release

Procyrion Inc. today announced they have won the People’s Choice Award from the American Heart Association’s (AHA) during the 2017 Health Tech Competition with their ground-breaking technology, Aortix™. The competition recognizes innovative healthcare solutions that improve patient outcomes for heart health.

November 13, 2017
  • Press Releases
  • Awards

Procyrion Wins 2017 People’s Choice Award at the American Heart Association Health Tech Competition

Digital Journal

Katherine Cox, Procyrion's Senior Director of Quality Assurance, awarded Quality Magazine's Professional of the Year Award at the 2017 Quality Show

November 7, 2017
  • Awards
  • Articles

Katherine Cox Awarded Quality Magazine's Professional of the Year Award

TMC News

A new medical device is poised to help heart failure patients without invasive surgery

September 6, 2017
  • Articles

Giving the Heart a Rest

Procyrion

Heart pump developer Procyrion, Inc. has been selected to participate in the 2017 EuroPCR, which will take place May 16th to 19th at the Palais des Congrès in Paris, France. Chief Scientific Officer Jace Heuring will deliver a presentation and discuss Aortix™.

May 9, 2017
  • Press Releases

Procyrion, Inc. Chosen to Present at EuroPCR 2017 in Paris

Quality Magazine

If you have a problem, you want to have Katherine Cox around. Her problem solving skills, team mindset and dedication to quality have earned her Quality Magazine's 2017 Quality Professional of the Year award.

April 1, 2017
  • Articles

High Stakes Quality: Meet Katherine Cox, Quality Magazine's 2017 Quality Professional of the Year

Becker's Hospital Review

Founded in 2005, this Houston-based biotechnology company developed the Aortix system. The Aortix, a minimally invasive catheter-based heart pump, is designed to rest the heart by reducing afterload and improve blood flow to vital organs, according to Procyrion.

January 31, 2017
  • Articles

Procyrion Named to Becker's List of Disruptive Healthcare Companies to Watch in 2017

pm360online.com

Founded in 2005, Procyrion, Inc. has identified an opportunity in the sweet spot—the time between when the drugs start to fail and a last-resort surgical intervention—to treat millions of NYHA Class III-IVa heart failure patients using a novel and minimally invasive catheter-based heart pump, Aortix.

December 21, 2016
  • Articles
  • Awards

Procyrion Named as One of Most Innovative Companies in 2016 by PM360

Procyrion

The Houston-based developer of a novel circulatory assist device intended to treat chronic heart failure, Procyrion, Inc., announced today it has added a key team member as it continues its path towards commercialization. James Toll has joined the Procyrion team as Operations Manager.

December 6, 2016
  • Press Releases

Procyrion Continues to Expand Adding Operations Manager

Procyrion

Heart pump developer, Procyrion, Inc. has been selected to participate in the 2016 Device Therapies for Heart Failure (D-HF), which will take place December 2 and 3 at the Novotel Paris Centre Tour Eiffel in Paris, France.

December 1, 2016
  • Press Releases

Procyrion, Inc. Chosen to Present at the 2016 Device Therapies for Heart Failure in Paris

Bloomberg

Houston heart pump developer Procyrion Inc. today announced the expansion of their office to support their growth and the further development of their ground breaking technology, Aortix™, a catheter-based circulatory support device.

November 4, 2016
  • Press Releases
  • Articles

Procyrion Expands Office Space in Preparation for Commercialization and Growing Team

Entrepreneur Magazine

Houston heart pump developer Procyrion Inc. today announced they have been recognized as one of the “Best Entrepreneurial Companies in America” by Entrepreneur magazine’s Entrepreneur 360™ List, the most comprehensive analysis of private companies in America.

October 25, 2016
  • Press Releases

Procyrion Named One Of The “Best Entrepreneurial Companies In America” By Entrepreneur Magazine’s 2016 Entrepreneur 360™ List

Procyrion

Micro heart pump maker Procyrion has added a key team member as it continues on its path towards commercialization. The Houston-based developer of a novel circulatory assist device intended to treat chronic heart failure announced today that Christian Landry has joined the Procyrion team as Product Development Manager.

October 20, 2016
  • Press Releases

Procyrion Adds Veteran Electrical Engineer to Further Develop Technology

Quality Magazine

New changes to ISO 13485, published this spring as EN ISO 13485:2016, mean U.S. medical device companies that sell in Europe will need to integrate risk-based approaches throughout their quality management systems. The emphasis on risk management is the biggest of several changes in the third version of ISO 13485.

October 1, 2016
  • Articles

ISO 13485 places new emphasis on risk management

Procyrion

Procyrion, the Houston-based developer of Aortix™, a percutaneous circulatory assist device intended to treat chronic heart failure (HF) and related conditions, today announced Gary Burbach as the company’s Chairman of the Board of Directors. Burbach previously served as an independent director for Procyrion.

July 13, 2016
  • Press Releases

Procyrion Board of Directors Elects Gary Burbach as Chairman

Quality Magazine

In today’s marketplace, where regulatory requirements are increasingly more stringent and consumer satisfaction is paramount, establishing a high-level quality management system should be a priority for businesses of all sizes.

June 22, 2016
  • Articles

Achieving Quality in The Startup Environment

Universal Biotech

Procyrion, located in Houston, Texas was one of the laureates of 2015 Innovation Prize organized by Universal Biotech, subsidiary of Universal Medica Group. The start-up is developing Aortix™ a first-in-class circulatory assist device for ambulatory treatment of chronic heart failure.

June 9, 2016
  • Articles

Disruptive Heart Assist Device by Procyrion

Rice University Department of Bioengineering

Micro heart pump maker Procyrion has recently added key team members as it prepares for first-in-human studies. The Houston-based developer of a circulatory assist device intended to treat chronic heart failure announced Rice University alumnus Chris Durst as senior director of product development.

May 31, 2016
  • Articles

Procyrion Hires Rice BIOE graduate alumnus Chris Durst

Medical Device and Diagnostic Industry

Procyrion envisions their Aortix™ device as a less-invasive approach that would keep heart failure patients ambulatory while under treatment. The small Aortix device, under development now, is being designed for the Class III and IVa heart failure patient.

May 20, 2016
  • Articles

Keeping Heart Failure Patients on Their Feet

CW39 NewsFix

Houston-based Procyrion will be housed in one of the 21 facilities at JLabs and under the direction of a Medical Center regular, Dr. Reynolds Delgado. He invented Aortix, a kinder, simpler way to keep the blood flowing through the heart while patients wait what could be years for a transplant.

May 11, 2016
  • Articles

The Biotech Revolution makes its way to the Bayou City

Procyrion

Houston heart pump developer Procyrion Inc. today announced they have won the Medical Device and Diagnostic Imaging (MD+DI) Magazine’s 2016 MedTech Startup Showdown Challenge with their ground breaking technology, Aortix™, a catheter-based circulatory support device.

May 2, 2016
  • Press Releases
  • Awards

Procyrion Wins MD+DI MedTech Startup Showdown Challenge

Houstonia

Houston has everything it needs to create thriving biotech and pharmaceutical industries. Now, if only its research and business communities can learn to work together.

April 28, 2016
  • Articles

In the City with the World’s Largest Medical Center, There’s Still No Biotech—Yet

Procyrion

Procyrion, the Houston-based developer of a percutaneous circulatory assist device intended to treat chronic heart failure, announced today that Gary Burbach will be joining its board of directors. Burbach currently serves as a director or advisor to multiple private, venture-backed and public life science companies.

March 22, 2016
  • Press Releases

Procyrion Appoints New Board Member

Procyrion

Procyrion Inc. today announced they have won the Johnson & Johnson Quick Fire Challenge with their ground breaking technology, Aortix™, a catheter-based circulatory support device. Procyrion has been awarded a year residency in the new JLABS facility located within the Texas Medical Center’s Innovation Institute.

March 3, 2016
  • Press Releases
  • Awards

Procyrion Wins Johnson & Johnson Quick Fire Challenge and Receives Year Residency at the New JLABS @ TMC

Procyrion

Procyrion adds key team members as it prepares for first-in-human studies. The Houston-based developer of a circulatory assist device intended to treat chronic heart failure announced today that Chris Durst, PhD, is senior director of product development and Ronnie Earles is associate director of product development.

February 10, 2016
  • Press Releases

Procyrion Hires Seasoned Product Development Directors

Procyrion

Procyrion, Inc., a medical device firm focused on developing a next-generation circulatory support pump for NYHA Class III heart failure patients, today announced that Katherine Cox has been hired as Senior Director of Quality Assuranceto to lead the company’s quality assurance efforts.

December 3, 2015
  • Press Releases

Katherine Cox Joins Procyrion as Senior Director of Quality Assurance

Crain's Houston

In this ongoing series, Crain's asks executives, entrepreneurs and business leaders about mistakes that have shaped their business philosophy. Procyrion's CEO Ben Hertzog shares his lessons learned.

November 17, 2015
  • Articles

If I knew then...

Medical Design Briefs

The 13th annual "Create the Future" Design Contest for engineers, students and entrepreneurs worldwide attracted a record number of entries - nearly 1,160 innovative product ideas from engineers and students in more than 60 countries.

November 2, 2015
  • Articles
  • Awards

2015 Create the Future Design Contest Winners

Medical Design Briefs

Procyrion, Inc. of Houston, TX is developing the first catheter-deployed heart pump intended for long-term treatment of chronic heart failure. Thinner than a #2 pencil and only 6cm long, AortixTM has the potential to become a low-risk circulatory assist device for a broad range of patients.

November 1, 2015
  • Awards
  • Articles

2015 Create the Future Design Contest: Grand Prize Winner

DAIC

Manesh Patel, M.D., associate professor of medicine, and director of interventional cardiology and the cath labs at Duke University, explains the innovations in interventional heart failure technologies, including the Aortix percutaneous heart pump.

October 30, 2015
  • Articles

Advances in Interventional Heart Failure Hemodynamic Support at TCT 2015

MassDevice

Pay attention to Procyrion over the next several months. CEO Benjamin Hertzog tells MassDevice.com that the company plans on heading to the clinic with a device that could heighten competition among makers of cardiac assist devices.

October 22, 2015
  • Articles

Procyrion’s Aortix device could heighten heart pump competition

Texas CEO Magazine

Sitting behind the wheel of a racecar is a lot like sitting behind the wheel of a startup. Both are temperamental, requiring lots of close attention; both have big goals, involving a team and a host of varied skills; both can go off track in a matter of seconds, demanding both patience and quick thinking.

October 17, 2015
  • Articles

How Auto Racing Prepared Me For The Startup Life

MD+DI

For startup executives, quality systems can be a financial drain. When poorly implemented, they can even be an impediment to product and business development. But a well-implemented quality system, on the other hand, can be an important tool for business risk mitigation.

October 15, 2015
  • Articles

Implementing a Quality System

Today's Medical Developments

Experiments boost Procyrion's micro-heart pump presented at scientific conference; Circulatory pump earns spot in TCT Interventional Innovation "Shark Tank” competition; earned a share of the 2015 Universal Biotech Innovation Prize.

October 13, 2015
  • Articles

Procyrion's micro-heart pump moving forward

FierceBiotech

Procyrion is developing the first catheter-deployed micropump for the heart. It's nabbed a $10 million Series B round to back clinical development of its tiny, chronic heart failure device that consists of a continuous flow pump that is mounted via the femoral artery inside the heart to the descending thoracic aorta.

October 9, 2015
  • Articles

Procyrion raises $10M to get minimally invasive mini heart pump in the clinic

Universal Biotech

Procyrion Inc. today earned the 2015 Universal Biotech Innovation Prize for Aortix™, a catheter-based circulatory support device. With the top two most innovative projects, Procyrion and Pixium Vision, will share a grant award and a year of consulting services offered by organizer Universal Biotech, valued at €60,000.

October 5, 2015
  • Press Releases
  • Awards

Houston Medical Developer Earns €30,000 For Circulatory Support Pump In International Life Sciences Competition

BioSpace

enmodes GmbH, a German company that designs and engineers innovative medical designs, put Houston-based Procyrion Inc.’s Aortix™ micro heart pump through a series of computational fluid dynamic simulations to improve the overall design and performance of the prototype in preparation for first-in-human trials.

September 21, 2015
  • Articles

Analysis To Limit Shear Stress, Improve Axial Blood Pump Flow Presented At ISRBP

Medical Design & Outsourcing

Ben Hertzog is the CEO of Procyrion, a Houston-based company that is developing Aortix, a custom designed pump built around a powerful micro-motor mounted on a set of expandable struts. Aortix is designed to rest and heal the heart by reducing afterload and improving blood flow to vital organs.

August 4, 2015
  • Articles

Procyrion CEO discusses its life-changing pump designed to heal the heart

BioNews Texas

Houston, Texas-based startup Procyrion, Inc. has been selected as one of the semi finalists for the 7th Universal Biotech Innovation Prize 2015, for the development of the Aortix heart pump system for patients with chronic heart failure.

July 2, 2015
  • Articles
  • Awards

Procyrion Nominated Semi Finalist for Biotech Innovation Prize

Medical Design Technology

Procyrion (Houston, TX) is addressing heart failure with Aortix, a catheter-deployed micro-pump. Thinner than a #2 pencil, Aortix augments heart function by reducing afterload, allowing the heart to work at a sustainable level while perfusing vital organs.

July 1, 2015
  • Articles
  • Awards

Medical Innovation Competition Pits Country Against Country

Medical Device Developments

Procyrion CEO Benjamin Hertzog discusses the need for minimally invasive cardiology tools, and explains how micro-motor technology and customised components could open up safe and effective treatment options.

June 22, 2015
  • Articles

Motors keep hearts running: minimally-invasive micro-motors

Procyrion

Procyrion, Inc., developers of the first catheter-deployed circulatory assist device for the ambulatory treatment of heart failure, appointed bioengineer interns Omar Benavides, Ph.D. to senior product development engineer and Tanner Songkakul to product development engineer.

May 4, 2015
  • Press Releases

Procyrion Hires Bioengineer Interns Benavides, Songkakul To Advance Development of Micro Heart Pump

Cardiovascular Disease News

The research team behind Houston-based Procyrion, Inc.’s Aortix long-term circulatory support pump for chronic heart failure patients will deliver a presentation at the 2015 International Society for Heart and Lung Transplantation (ISHLT) 35th Annual Meeting & Scientific Session in Nice, France.

April 10, 2015
  • Articles

Procyrion Aortix Cardiorenal Assist Pump Presented At ISHLT 35th Annual Meeting

Medical Design Technology

Procyrion, Inc. of Houston, TX is developing the first catheter-deployed circulatory assist device designed for long-term treatment of early-stage heart failure. Thinner than a #2 pencil, Aortix has the potential to become a low-risk treatment option for a broad range of patients.

April 10, 2015
  • Articles

Circulatory Support Without Surgery

Houston Business Journal

A number of Houston companies made their presence known at Austin's SXSW Interactive festival this year. Procyrion's Jace Heuring giving his pitch at the 2015 Hatch Pitch competition.

March 18, 2015
  • Articles
  • Awards

Houston companies take top spots at SXSW pitch competitions

Procyrion

Carlos del Rio, Ph.D. of QTest Laboratories will present his findings using Aortix™, a catheter-deployed circulatory assist pump for the treatment of chronic heart failure being developed by Procyrion, Inc., at the American College of Cardiology’s 64th Annual Scientific Session and Expo (ACC.15)

March 12, 2015
  • Articles

Cardiorenal Benefits of Aortix Device to be Presented at ACC.15 in San Diego, CA

Today's Medical Developments

Omar Benavides, Ph.D., a senior product development engineer with Procyrion, presented results from the first large animal study completed with the modified circulatory assist device under the grant at the Consortium’s 2nd Annual Pediatric Device Innovation Competition held at the University of Maryland.

February 23, 2015
  • Articles

Medical device modified for use in children

Procyrion

Medical device firm Procyrion, Inc., developing the first catheter-deployed circulatory assist device for the ambulatory treatment of heart failure, announced today that interventional cardiologist Dr. Manesh Patel of Duke University Medical Center has joined the company’s scientific advisory board.

February 16, 2015
  • Press Releases

Procyrion Appoints Dr. Manesh Patel of Duke University Medical Center To Scientific Advisory Board

Procyrion

Omar Benavides, Ph.D., a senior product development engineer with Procyrion, presented results from the first large animal study completed with the modified circulatory assist device under the grant at the Consortium’s 2nd Annual Pediatric Device Innovation Competition held at the University of Maryland.

February 12, 2015
  • Press Releases

$50,000 Grant Progress Update At Annual Pediatric Innovation Expo

Xconomy.com

Houston’s Procyrion, a medical device company that makes Aortix™, a thinner-than-a-pencil circulatory support pump that can be implanted in the aorta via a catheter. The device is designed to act like a crutch, helping patients with damaged hearts push more blood through the circulatory system and on to vital organs.

February 11, 2015
  • Articles

Hatch Pitch Unveils Tech Startup Lineup for Upcoming SXSW Demo Day

Machine Design

Cardiologists will soon be fitting patient's aortas with tiny pumps to help diseased hearts rest and heal, thanks to engineers at Procyrion Inc., Houston, who designed a circulatory-assist device. It’s called the Aortix™ and it accelerates native blood flow with entraining jets, creating better overall circulation.

August 28, 2014
  • Articles

Pumps Inside Arteries Help Cardiac Patients

MDDI

In forecasting the future of cardiovascular disease in the United States, a report by the American Heart Association shows Baby Boomers and cardiovascular disease on a direct collision course. By 2030, it is projected that more than 40% of Americans will have some form of cardiovascular disease.

August 21, 2014
  • Articles

When Technologies Collide, Outcomes Improve for Cardio Patients

Medical Design Briefs

A team of life science entrepreneurs in Houston has developed the first catheter-deployed circulatory assist device intended for long-term use to treat chronic heart failure. Aortix™ provides a minimally invasive treatment for the more than two million chronic heart failure patients who are too sick for medication.

August 1, 2014
  • Articles

Circulatory Support Without Surgery for Heart Failure Patients

Today's Medical Developments

Procyrion Inc., a medical device firm developing the first catheter-deployed circulatory assist device intended for long-term use in the treatment of chronic heart failure, has been awarded a $50,000 grant from the National Capital Consortium for Pediatric Device Innovation.

July 15, 2014
  • Awards
  • Articles

$50,000 Pediatric Device Innovation Grant Awarded to Procyrion

Qmed

A life-long do-it-yourselfer, Will Clifton is now involved with the development of the Procyrion Aortix—a small LVAD meant to be implanted inside an artery in a minimally invasive procedure. Clifton has managed Procyrion's Preclinical R&D program including sourcing sites, drafting protocols, and executing studies.

June 30, 2014
  • Awards
  • Articles

Procyrion Director named one of QMed's "30 Under 30 Medtech Innovators"

BoA Small Business Community

Establishing the equity stake might boil down to simple mathematics, notes Ben Hertzog, president and CEO of Procyrion, a Houston-based medical device startup that recently received $2.9 million in funding.

June 25, 2014
  • Articles

Finding the Right Balance When Trading Equity for Cash

Today's Medical Developments

Aortix is a catheter-deployed, long-term treatment option for chronic heart failure that is designed to reduce the workload of the heart – allowing it to rest and heal without surgery. Even more exciting, this device opens up the opportunity to treat younger, healthier patients before years of progressive damage occur.

June 19, 2014
  • Articles

Helping the Heart Heal Itself

Procyrion

Following blind peer review, Procyrion Inc.’s abstract, “Aortix™ Percutaneous Circulatory Assist Device Decreases Afterload, Improves Renal Function in Chronic HF,” has been selected for oral presentation at the American Society for Artificial Internal Organs (ASAIO) 60th annual conference...

May 12, 2014
  • Press Releases

Procyrion, Inc. To Present Aortix™ Abstract At American Society for Artificial Internal Organs 60th Annual Conference

BioNews Texas

Houston-based Medical device company Procyrion, Inc., recently made a significant personnel move to promote one of the company’s executives to its board of directors. Last week, Steven Oldham was appointed to the board, and will represent Procyrion’s Series A stockholders...

May 5, 2014
  • Articles

Houston’s Procyrion Adds Seasoned Financial Executive To Board of Directors

Procyrion

Procyrion’s team of life science entrepreneurs have been accepted to present Aortix™, an intra-aortic ambulatory support device for cardiorenal heart failure patients, at the International Society for Heart and Lung Transplantation’s (ISHLT) 34th Annual Meeting & Scientific Session in San Diego April 10 – 13, 2014.

April 1, 2014
  • Press Releases

Procyrion, Inc. to Present Circulatory Support Pump at International Society for Heart and Lung Transplantation’s Annual Meeting

BioNews Texas

Procyrion and its novel Aortix device continue to gain momentum in the medical marketplace, the company has announced it will present its catheter-deployed circulatory assist device at the American College of Cardiology 63rd Annual Scientific Session and Expo (ACC.14) scheduled for March 29–31 in Washington D.C.

March 27, 2014
  • Articles

Houston’s Procyrion, Inc. To Present Aortix Catheter-Deployed Circulatory Assist Device at ACC.14

Xconomy

The Houston medtech startup’s device is called Aortix™, a circulatory support pump that is thinner than a pencil and can be implanted in the aorta, the major artery coming from the heart, through a catheter threaded up from the thigh through the femoral artery.

March 25, 2014
  • Articles

Houston Medtech Firm Procyrion Aims to Help Heart Heal Itself

DAIC

The latest in pVAD hemodynamic support technology in development and a look at future devices to treat heart failure.

March 18, 2014
  • Articles

Advances in Percutaneous Ventricular Assist Devices

BioNews Texas

Procyrion recognized by the Rice Alliance as a “Top Life Science Company” for its Aortix™ medical device.

March 3, 2014
  • Awards
  • Articles

Procyrion, Inc. Recognized as Top Life Science Company

Procyrion

Houston-based Procyrion, Inc. has been recognized by the Rice Alliance as a “Top Life Science Company” at the 2014 Texas Life Science Forum for its Aortix™, the first catheter-deployed circulatory assist device intended for long-term use in the treatment of chronic heart failure.

February 27, 2014
  • Press Releases

Procyrion, Inc. Recognized as “Top Life Science Company” At 2014 Texas Life Science Forum

Procyrion

Houston-based Procyrion, Inc. has been selected to present and discuss future plans for Aortix™, the first catheter-deployed circulatory assist device intended for long-term use in the treatment of chronic heart failure, at the 2014 Texas life Science Forum.

February 18, 2014
  • Press Releases

Procyrion, Inc. Selected to Present Novel Circulatory Support Technology at 2014 Texas Life Science Forum

DIAC

Procyrion Inc. is developing a catheter-deployed circulatory assist device intended for long-term use in the treatment of chronic heart failure. The 6-mm diameter Aortix device is narrower than a pencil and is delivered via a catheter in a minimally invasive outpatient procedure lasting about 10 minutes.

February 7, 2014
  • Articles

Transcatheter Pump May Aid Heart Failure Patients

BioNews Texas

Houston-based Procyrion, Inc. has proven that its viability in the biotech sector is worthy of Texas state funding. Yesterday, the privately-held medical device company, which is also associated with the Houston Technology Center, announced the closing of $750,000 second tranche from the Texas Emerging Technology Fund.

January 24, 2014
  • Articles

Texas Emerging Technology Fund Delivers Second Tranche of $1.5 Million Funding To Houston-Based Procyrion, Inc.

Procyrion

Procyrion, Inc., a privately-held medical device firm developing the first catheter-deployed circulatory assist device intended for long-term use in the treatment of chronic heart failure, today announced the closing of $750,000 second tranche from the Texas Emerging Technology Fund.

January 14, 2014
  • Articles

Procyrion, Inc. Receives Second Tranche of $1.5 Million of Texas Emerging Technology Fund

BioNews Texas

Houston medical device company Procyrion, Inc. recently announced the establishment of a new scientific advisory board. Appointments to the new board include several leading cardiologists and cardiovascular researchers, including Emma Birks, MBBS, PhD; Hani Sabbah, PhD; Keith Aaronson, MD and Joseph Rogers, MD.

January 8, 2014
  • Articles

Houston-Based Procyrion, Inc. Launches New Scientific Advisory Board

Houston Chronicle

Juan Fernandez, the machinist at Houston's Methodist Hospital, works on a project in his machine shop at Methodist, Wednesday, Dec. 18, 2013, in Houston. Fernandez's handiwork has made some very significant contributions to in the history of cardiovascular surgery.

January 4, 2014
  • Articles

Machinist is unsung hero of heart treatment advances

MedGadget

Procyrion, a company based in Houston, Texas, has developed and is working on bringing to market a new intra-aortic support pump that may help people with heart failure “reduce afterload, reduce workload of the heart, and increase end-organ perfusion,” according to the company.

January 2, 2014
  • Articles

Aortix™ Minimally Invasive Intra-Aortic Circulatory Support Pump

Procyrion

Procyrion, Inc., a medical device company developing the first catheter-deployed circulatory assist device, announces the appointment of leading cardiologists and cardiovascular researchers Emma Birks, MBBS, PhD; Hani Sabbah, PhD; Keith Aaronson, MD and Joseph Rogers, MD to its newly formed scientific advisory board.

December 31, 2013
  • Press Releases

Procyrion Announces Formation of Scientific Advisory Board

ASAIO

Published in ASAIO's May 2013 issue, Procyrion's journal article, "Improved hemodynamics with a novel miniaturized intra-aortic axial flow pump in a porcine model of acute left ventricular dysfunction".

May 15, 2013
  • Publications

Preliminary Data Published in American Society for Artificial Internal Organs Journal

Entrepreneur

Houston's budding entrepreneurs aren't hanging up shingles for lack of better options. With energy and life sciences playing a big role in the city's economy, the recession didn't hit Houston as hard as it did in many places.

February 24, 2013
  • Articles

A Peek Inside Houston's Startup Scene

Houston Business Journal

Ben Hertzog, CEO of Houston-based Procyrion, said he's excited about the company's recently awarded $750,000 Emerging Technology Fund grant.

January 13, 2013
  • Awards

Texas Emerging Technology Fund Award

Houston Technology Center

The Goradia Innovation Prize, with Opportunity Houston, distributes almost $150,000 in cash prizes to finalists and honorable mentions of early stage companies that have commercialized or will soon commercialize innovative technology within the Gulf Coast region at the 2012 Innovation Conference and Showcase.

October 8, 2012
  • Awards

Goradia Innovation Prize

The Aortix™ device is currently in the research and development phase and is not available for sale in any country.
Caution: Investigational Device. Limited by Federal Law to Investigational Use.

Links

HomeClinical TrialsOverviewTeamNewsCareersReferencesDisclaimer & Terms of UseContact

LATEST NEWS

March 2024
Fierce Biotech
Procyrion Recognized in Fierce Medtech's Fierce15 of 2023
February 2024
Press Release
Procyrion Closes $57.7 Million in Series E Financing
November 2023
Press Release
Procyrion Announces First Patient Enrollments in the DRAIN-HF Pivotal IDE Trial for Aortix™ Percutaneous Mechanical Circulatory Support Technology

ABOUT US

Procyrion is a team of experienced life science entrepreneurs, engineers, cardiologists, and heart failure specialists.

Our dedicated team is working to address the unmet clinical needs of heart failure patients through the development of a safe and innovative percutaneous mechanical circulatory support (pMCS) device.

Copyright © 2021 Procyrion, Inc.
Disclaimer & Terms of Use
Aortix™ is for investigational use only and is not for sale in the United States.